IDXGD.US Interpace Biosciences, Inc.
- Market cap
- USD 35.4M
- P/E
- 1.4x
- P/B
- 1.38x
- ROE
- 7.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IDXGD.US undervalued?
Graham numberThe Graham number of Interpace Biosciences, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Interpace Biosciences, Inc. fundamental analysis
No fundamental analysis for Interpace Biosciences, Inc. yet.
Interpace Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The …
Full company profileInterpace Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Interpace Biosciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 31.8M | 40.0M | 46.9M | 38.7M | 36.3M |
| Gross Profit | 18.2M | 25.1M | 29.9M | 24.1M | 23.1M |
| Operating Income | -3.84M | 3.96M | 8.11M | 4.08M | 2.89M |
| EBITDA | -1.33M | 4.89M | 8.36M | 4.76M | 3.85M |
| Net Income | -22.0M | 1.95M | 6.70M | 24.6M | 1.76M |
| EPS | -26 | 2.25 | 1.52 | 28 | 0.32 |
| Balance Sheet | |||||
| Total Assets | 16.0M | 13.1M | 14.8M | 33.8M | 34.5M |
| Total Liabilities | 79.1M | 68.7M | 17.0M | 11.5M | 11.3M |
| Shareholders' Equity | -63.1M | -55.5M | -2.22M | 22.4M | 23.2M |
| Cash & Short-term Investments | 4.83M | 3.50M | 1.46M | 2.51M | 2.69M |
| Cash Flow | |||||
| Operating Cash Flow | -7.69M | 3.79M | 4.65M | 5.83M | 762K |
| Capital Expenditure | 322K | 470K | 876K | 356K | 396K |
| Free Cash Flow | -8.01M | 3.32M | 3.77M | 5.48M | 366K |
| Ratios | |||||
| ROE | - | - | - | 109.9% | 7.6% |
| ROA | -137.4% | 14.9% | 45.3% | 72.6% | 5.1% |
| Net Profit Margin | -69.0% | 4.9% | 14.3% | 63.5% | 4.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Interpace Biosciences, Inc. dividends
Interpace Biosciences, Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:5 on Aug 27, 2026.
Who owns Interpace Biosciences, Inc.
- Insiders 91.18%
- Institutions 0.00%
- Public & others 8.82%
- Shares outstanding 5.54M
- Free float 361K
Interpace Biosciences, Inc. company profile
- Company name
- Interpace Biosciences, Inc.
- Ticker
- IDXGD.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 102
- Fiscal year end
- December
- Address
- Waterview Plaza, Parsippany, NJ, United States, 07054
- Phone
- 855 776 6419
- Website
- interpace.com
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Interpace Biosciences, Inc. management
5- Dr. Thomas W. Burnell Ph.D.President, CEO & Chairman · born 1962
- Mr. Christopher McCarthyCFO & COO · born 1992
- Dr. Sydney D. Finkelstein M.D.Chief Pathology Officer
- Dr. Nicole Massoll M.D.Chief Medical Officer
- Mr. Patrick KaneVP & Corporate Controller